vs
IMAX（IMAX）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是IMAX的1.6倍（$197.9M vs $125.2M），REPLIGEN CORP净利率更高（6.7% vs 0.5%，领先6.2%），IMAX同比增速更快（35.1% vs 13.6%），IMAX自由现金流更多（$28.0M vs $17.6M），过去两年IMAX的营收复合增速更高（25.8% vs 14.4%）
IMAX公司是加拿大的影视放映技术企业，1967年创立于蒙特利尔，总部位于多伦多地区，在纽约、洛杉矶均设有业务点。核心业务包括IMAX摄影机与放映系统的设计制造，同时面向全球合作影院提供影片开发、制作、后期及发行服务，是沉浸式观影技术领域的领先企业。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
IMAX vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.6倍
$125.2M
营收增速更快
IMAX
高出21.5%
13.6%
净利率更高
RGEN
高出6.2%
0.5%
自由现金流更多
IMAX
多$10.4M
$17.6M
两年增速更快
IMAX
近两年复合增速
14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $125.2M | $197.9M |
| 净利润 | $637.0K | $13.3M |
| 毛利率 | 57.6% | 52.5% |
| 营业利润率 | 19.3% | 9.0% |
| 净利率 | 0.5% | 6.7% |
| 营收同比 | 35.1% | 13.6% |
| 净利润同比 | -88.0% | 143.9% |
| 每股收益（稀释后） | $0.02 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMAXRGEN
| Q4 25 | $125.2M | $197.9M | ||
| Q3 25 | $106.7M | $188.8M | ||
| Q2 25 | $91.7M | $182.4M | ||
| Q1 25 | $86.7M | $169.2M | ||
| Q4 24 | $92.7M | $174.1M | ||
| Q3 24 | $91.5M | $154.9M | ||
| Q2 24 | $89.0M | $154.1M | ||
| Q1 24 | $79.1M | $151.3M |
净利润IMAXRGEN
| Q4 25 | $637.0K | $13.3M | ||
| Q3 25 | $20.7M | $14.9M | ||
| Q2 25 | $11.3M | $14.9M | ||
| Q1 25 | $2.3M | $5.8M | ||
| Q4 24 | $5.3M | $-30.3M | ||
| Q3 24 | $13.9M | $-654.0K | ||
| Q2 24 | $3.6M | $3.3M | ||
| Q1 24 | $3.3M | $2.1M |
毛利率IMAXRGEN
| Q4 25 | 57.6% | 52.5% | ||
| Q3 25 | 63.1% | 53.2% | ||
| Q2 25 | 58.5% | 50.0% | ||
| Q1 25 | 61.4% | 53.6% | ||
| Q4 24 | 52.2% | 26.1% | ||
| Q3 24 | 55.8% | 50.0% | ||
| Q2 24 | 49.4% | 49.8% | ||
| Q1 24 | 59.3% | 49.5% |
营业利润率IMAXRGEN
| Q4 25 | 19.3% | 9.0% | ||
| Q3 25 | 27.2% | 8.9% | ||
| Q2 25 | 15.6% | 7.6% | ||
| Q1 25 | 19.3% | 3.9% | ||
| Q4 24 | 10.3% | -17.7% | ||
| Q3 24 | 21.2% | -5.1% | ||
| Q2 24 | 3.2% | 1.0% | ||
| Q1 24 | 15.3% | 1.3% |
净利率IMAXRGEN
| Q4 25 | 0.5% | 6.7% | ||
| Q3 25 | 19.4% | 7.9% | ||
| Q2 25 | 12.3% | 8.2% | ||
| Q1 25 | 2.7% | 3.4% | ||
| Q4 24 | 5.7% | -17.4% | ||
| Q3 24 | 15.2% | -0.4% | ||
| Q2 24 | 4.0% | 2.2% | ||
| Q1 24 | 4.1% | 1.4% |
每股收益（稀释后）IMAXRGEN
| Q4 25 | $0.02 | $0.24 | ||
| Q3 25 | $0.37 | $0.26 | ||
| Q2 25 | $0.20 | $0.26 | ||
| Q1 25 | $0.04 | $0.10 | ||
| Q4 24 | $0.09 | $-0.55 | ||
| Q3 24 | $0.26 | $-0.01 | ||
| Q2 24 | $0.07 | $0.06 | ||
| Q1 24 | $0.06 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $151.2M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $337.9M | $2.1B |
| 总资产 | $894.0M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资IMAXRGEN
| Q4 25 | $151.2M | $767.6M | ||
| Q3 25 | $143.1M | $748.7M | ||
| Q2 25 | $109.3M | $708.9M | ||
| Q1 25 | $97.1M | $697.2M | ||
| Q4 24 | $100.6M | $757.4M | ||
| Q3 24 | $104.5M | $784.0M | ||
| Q2 24 | $91.6M | $809.1M | ||
| Q1 24 | $81.0M | $780.6M |
总债务IMAXRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IMAXRGEN
| Q4 25 | $337.9M | $2.1B | ||
| Q3 25 | $349.5M | $2.1B | ||
| Q2 25 | $320.4M | $2.1B | ||
| Q1 25 | $299.5M | $2.0B | ||
| Q4 24 | $299.5M | $2.0B | ||
| Q3 24 | $289.4M | $2.0B | ||
| Q2 24 | $267.2M | $2.0B | ||
| Q1 24 | $258.8M | $2.0B |
总资产IMAXRGEN
| Q4 25 | $894.0M | $2.9B | ||
| Q3 25 | $889.6M | $2.9B | ||
| Q2 25 | $868.6M | $2.9B | ||
| Q1 25 | $848.3M | $2.9B | ||
| Q4 24 | $830.4M | $2.8B | ||
| Q3 24 | $847.6M | $2.8B | ||
| Q2 24 | $827.4M | $2.9B | ||
| Q1 24 | $824.1M | $2.8B |
负债/权益比IMAXRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.4M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $28.0M | $17.6M |
| 自由现金流率自由现金流/营收 | 22.3% | 8.9% |
| 资本支出强度资本支出/营收 | 1.1% | 4.1% |
| 现金转化率经营现金流/净利润 | 46.11× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $118.9M | $93.9M |
8季度趋势，按日历期对齐
经营现金流IMAXRGEN
| Q4 25 | $29.4M | $25.7M | ||
| Q3 25 | $67.5M | $48.1M | ||
| Q2 25 | $23.2M | $28.6M | ||
| Q1 25 | $7.0M | $15.0M | ||
| Q4 24 | $11.5M | $39.2M | ||
| Q3 24 | $35.3M | $49.3M | ||
| Q2 24 | $35.0M | $42.2M | ||
| Q1 24 | $-11.0M | $44.7M |
自由现金流IMAXRGEN
| Q4 25 | $28.0M | $17.6M | ||
| Q3 25 | $64.8M | $43.4M | ||
| Q2 25 | $20.9M | $21.5M | ||
| Q1 25 | $5.3M | $11.4M | ||
| Q4 24 | $6.9M | $33.6M | ||
| Q3 24 | $34.2M | $42.3M | ||
| Q2 24 | $33.5M | $37.4M | ||
| Q1 24 | $-12.1M | $36.4M |
自由现金流率IMAXRGEN
| Q4 25 | 22.3% | 8.9% | ||
| Q3 25 | 60.7% | 23.0% | ||
| Q2 25 | 22.8% | 11.8% | ||
| Q1 25 | 6.1% | 6.8% | ||
| Q4 24 | 7.4% | 19.3% | ||
| Q3 24 | 37.3% | 27.3% | ||
| Q2 24 | 37.6% | 24.3% | ||
| Q1 24 | -15.3% | 24.0% |
资本支出强度IMAXRGEN
| Q4 25 | 1.1% | 4.1% | ||
| Q3 25 | 2.6% | 2.5% | ||
| Q2 25 | 2.6% | 3.9% | ||
| Q1 25 | 1.9% | 2.1% | ||
| Q4 24 | 5.0% | 3.2% | ||
| Q3 24 | 1.2% | 4.5% | ||
| Q2 24 | 1.8% | 3.1% | ||
| Q1 24 | 1.4% | 5.5% |
现金转化率IMAXRGEN
| Q4 25 | 46.11× | 1.93× | ||
| Q3 25 | 3.27× | 3.23× | ||
| Q2 25 | 2.06× | 1.92× | ||
| Q1 25 | 2.99× | 2.57× | ||
| Q4 24 | 2.16× | — | ||
| Q3 24 | 2.54× | — | ||
| Q2 24 | 9.78× | 12.70× | ||
| Q1 24 | -3.35× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
RGEN
暂无分部数据
